N4 PHARMA PLC

Regulatory Filings • Feb 21, 2025

National Storage Mechanism | Additional information

RNS Number : 9219X

Ananda Pharma PLC

21 February 2025

21 February 202 5

ANANDA PHARMA PLC  

("Ananda" or the "Company")  

CEO Presenting at Swiss Private Investor Conference

Ananda Pharma plc (AQSE: ANA), a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, is pleased to announce that the CEO of Ananda, Melissa Sturgess, will today be presenting to the Talman House private members' event in Zurich.

Talman House is a private members organization for investors interested in the cannabis and adjacent industries..  Ananda Pharma is one of a select few companies presenting to an exclusive room of Talman House members.  Learn more about Talman House at:

https://thetalmangroup.com/talman-house/ .

Ananda's CEO, Melissa Sturgess commented : "Now is the time for regulatory approved cannabinoid medicines.  With chronic diseases creating a health and economic crisis across the globe the multi modal actions of cannabinoids have the potential to treat many conditions.  We believe the fully regulated drug development pathway will deliver the highest level of access to patients and the best returns to shareholders.  We are on our way with four confirmed cannabinoid clinical trials and I look forward to presenting to the Talman House audience later today."  

Justin Tombe, COO of The Talman Group commented "we look forward to welcoming Ananda to present to our private investor members later today.  Today's Zurich event will mark the second official gathering of the Talman House, where investor members meet to discuss market developments and opportunities in the cannabis and adjacent industries.  Ananda has been selected to present their credentials and vision to an exclusive room of Talman House members, and we are excited to spotlight their work in the field of medical cannabis and drug development." 

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved , cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn :   https://www.linkedin.com/company/anandapharma

·              X : https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

-Ends-  

The Directors of the Company accept responsibility for the contents of this announcement.  

ANANDA PHARMA PLC	+44 (0)7463 686 497
	ir@anandapharma.co.uk
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	+44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Josh Ray
Corporate Broking
Abigail Wayne
Rob Rees
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay	+44 (0)20 3004 9512 ananda@yellowjerseypr.com

https://investors.anandapharma.co.uk/link/KyzR2y

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAPKKBDABKDKBB